Introduction
Cardiac function is modulated by the sympathetic nervous system via catecholamines released from cardiac sympathetic nerve endings and adrenal chromaffin cells; the sympathoadrenal-cardiac axis. 1 Sympathetic stimulation of cardiomyocytes elevates free intracellular calcium ([Ca 2þ ] i ) which is essential for regulation of excitation-contraction coupling, maintaining electrophysiological balance, and control of transcriptional regulation. [2] [3] [4] Increasing cardiac output via sympathetic activation initially compensates for declining heart function. However, sustained sympathetic activity is deleterious and may cause and promote adverse cardiac remodelling and heart failure. 1 Persistent sympathetic activity promotes release of the cardiac function-modulating co-transmitter neuropeptide Y (NPY) from secretory bodies of sympathetic neurons and adrenal chromaffin cells. 5, 6 NPY is a 36-amino acid peptide that signals through G-protein-coupled NPY receptors and, in contrast to catecholamines, has a relatively long circulating half-life. 7 The NPY type 1 receptor (NPY1R) is predominant receptor subtype in the heart. 8 Experimental models demonstrate that NPY elevates [Ca 2þ ] i transients in cardiomyocytes, 9 enhances their shortening, 9 and increases contractile force in myocardial strips 10 via NPY1R activation. Increased cardiomyocyte [Ca 2þ ] i levels upon NPY stimulation coincide with higher expression of calcineurin and cardiomyocyte hypertrophy. 11 Accordingly, NPY infusion in rats leads to cardiac hypertrophy and fibrosis with higher calcineurin expression. 12 Interestingly, besides inducing hypertrophy by itself, NPY also potentiates the hypertrophic effects of norepinephrine on cardiomyocytes. 13 The clinical importance of NPY in cardiac disease has been demonstrated in heart failure patients, in which elevated plasma NPY levels positively correlate with disease severity 14 and are an independent prognostic marker for 1-year mortality. 15 Therefore, factors regulating NPY expression and release may prove important modifiers of cardiac function and disease. We previously reported enhanced expression of NPY mRNA in bone marrow-derived macrophages from mice lacking nuclear receptor Nur77, 16 suggesting a role for Nur77 in the regulation of NPY expression. Nur77, a transcription factor also known as NR4A1, TR3, or NGFI-B, is an immediate-early gene involved in stress responses in various cell types and organ systems. [17] [18] [19] Elevated NPY in Nur77-deficient mice (Nur77-KO) may explain various phenotypes reported in these animals. 20, 21 Regarding the heart, we have recently shown that Nur77-KO mice exhibit elevated diastolic and systolic cardiomyocyte [Ca 2þ ] i , higher calcineurin activity, and enhanced cardiac hypertrophy and fibrosis upon chronic stimulation with the b-adrenergic agonist isoproterenol (ISO). 22 In this study, we investigate the underlying mechanism and report that Nur77 modulates adverse cardiac remodelling by controlling NPY levels and signalling in the sympathoadrenal-cardiac axis.
Methods
Cell culture and transfections PC12 cells (gift from Prof. Eric Reits, Academic Medical Center Amsterdam) were maintained in RPMI medium (Gibco, Carlsbad, CA, USA) containing 10% horse serum, 5% FCS, and penicillin/streptomycin. Using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), Nur77 was overexpressed by transfection of a human Nur77 plasmid described previously. 23 An empty pEGFP-N3 vector (Promega, Madison, WI, USA) served as control. Nur77 was silenced by transfection of Nur77 siRNA (40 nM; SMARTpool, Dharmacon, Lafayette, CO, USA) or a non-targeting control siRNA using Lipofectamine RNAiMAX (Invitrogen). Transfections were carried out in serum-free Optimem medium (Gibco) for 6 h. Cells were used 24 h post-transfection.
Animal experiments
All animal care procedures and experiments were approved by the institutional Animal Ethics Committee of the University of Amsterdam, in accordance with institutional and European directive 2010/63/EU guidelines. All animal studies have been performed and analysed in a blinded manner.
Mice
C57Bl6/J WT (stock #000664) and Nur77-KO (stock #006187) mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA 
RNA isolation and qPCR
Total RNA was isolated from cells and tissues using TriReagent (SigmaAldrich, St. Louis, MO, USA), and cDNA was synthesized from 1 lg RNA input using iScript reverse transcription reagent (Biorad) according to manufacturer's instructions. qPCR was performed on a Roche Lightcycler with rplp0 and rpl13 serving as housekeeping genes. Primer sequences are listed in Supplementary material online, Table S1 .
Neonatal rat cardiomyocyte hypertrophy
Neonatal rat cardiomyocytes were isolates as described previously. 22 Briefly, 1-3 day old Wistar rats were euthanized by decapitation. Hearts were excised, atria were removed, and hearts were minced. The pieces were left overnight to rotate at 4 C in HBSS (Invitrogen) containing 1 mg/mL trypsin (Affymetrix, Santa Clara, CA, USA). The next day, cells were dissociated using 1 mg/mL collagenase (Worthington, Lakewood, NJ, USA) in HBSS. Cells were resuspended in M199 culture medium supplemented with 1% HEPES, 1% NEAA, 2 mg/L vitamin B12, 3.5 g/L glucose, and antibiotics (all from Invitrogen) and pre-plated to separate NRCMs. Non-adherent cells were collected and plated on fibronectin. Cells were serum-starved for 24 h in Dulbecco's modified Eagle medium (DMEM) supplemented with 1% penicillin/streptavidin (Invitrogen) before experiments. NRCMs were incubated for 48 h in DMEM containing 5% FCS, 5% mouse serum or conditioned medium from PC12 cells in a ratio of 2:1 to reach a final serum concentration of 5%. When used in the experimental set-up, receptor antagonists were preincubated for 15 min before other stimuli were added. Compounds were as follows: NPY (indicated concentrations; Bachem, Bubendorf, Switzerland), BIBO3304 (1 lM; Tocris, Bristol, UK), isoproterenol (25 lM; Sigma), metoprolol (10 lM; Sigma). To assess hypertrophy, cells were fixed with 4% paraformaldehyde (Roth) and stained with a-actinin antibody (Sigma #A7811), Hoechst and anti-mouse AlexaFluor488-conjugated secondary antibody ] i was measured for 1 min, followed by 5 min measurements directly upon stimulation with 100 nM NPY.
In vivo cardiac hypertrophy
In WT, Nur77-KO, CM-WT, and CM-KO mice, osmotic minipumps (Alzet) containing saline, isoproterenol (60 mg/kg/day), BIBO3304 (15 mg/kg/day), or a combination (n = 4-9 per experimental group) were implanted subcutaneously. Isoflurane inhalation anaesthesia (4% isoflurane for induction, 2% isoflurane, and O 2 for maintenance of anaesthesia; Baxter, Illinois, USA) was used with Carprofen (4 mg/kg) administered subcutaneously as a local analgesic. Mice to be implanted with a BIBO3304-containing pump received a priming dose of BIBO3304 (15 mg/kg i.p.) 15 min before pump implantation. An equivalent volume of saline was injected in mice to be implanted with pumps not containing BIBO3304. After 7 days, the mice were euthanized through a lethal dose of ketamine (238 mg/kg)/xylazine (102 mg/kg) injected i.p., where after blood and organs were immediately harvested.
Histological analysis
Hearts were embedded in paraffin, sectioned (7 mm) and mounted on Starfrost glass slides (Thermo Scientific). The heart area displaying the highest degree of damage was assessed on haematoxylin and eosin-stained sections, and sequential sections were used for further characterization. Quantifications were performed in the left ventricle and septum. To assess cardiomyocyte cross-sectional area, heart sections were stained with AlexaFluor488-conjugated wheat germ agglutinin (Molecular Probes) and Hoechst. Transversely cross-sectioned cardiomyocytes revealing thin, intact cell borders, and nuclei located in proximity of the cell centre were used for assessment of cross-sectional area by ImageJ software. Per mouse, > _250 cardiomyocytes were measured to acquire a proper representation of the tissue. Cardiac collagen deposition was stained with the Masson's Trichrome kit (Sigma-Aldrich) according to manufacturer's instructions. The ratio of fibrotic area compared to septum and left ventricle area was quantified using Leica QWin V3 software (Leica Microsystems, Cambridge, UK).
Calcineurin activity assay
Using the lysis buffer supplied in the Calcineurin Cellular Activity assay kit (Enzo Life Sciences, Exeter, UK), proteins were isolated from snap-frozen mouse left ventricles. Calcineurin phosphatase activity was measured in 5 lg protein from each lysate, incubated for 1 h at 30 C, according to the manufacturer's instructions.
Statistical analysis
Analyses were performed using GraphPad Prism 5 (La Jolla, CA, USA) software. Data distribution was tested with the Kolmogorov-Smirnov normality test. Data are presented as mean ± SEM and tested with Student's t-test or one-way ANOVA with Holm-Bonferroni correction (>2 groups). Nonnormally distributed data are presented as boxplots with whiskers for minimum/maximum values and tested with Mann-Whitney U test.
Results

b-Adrenergic stimulation modulates Nur77 and NPY expression in adrenal glands
To assess the effects of chronic b-adrenergic receptor stimulation on Nur77 expression in the sympathoadrenal axis, we stimulated wild-type (WT) Figure 1A ). This was accompanied by a significant elevation of adrenal NPY expression ( Figure 1B and C) and plasma NPY ( Figure 1D ). Chronic ISO infusion decreased plasma levels of the endogenous catecholamine norepinephrine, suggesting a different mode of action between the two sympathetic mediators upon sustained stress (see Supplementary material online, Figure S1A ). Adrenal chromaffin cells are a major source of peripheral NPY 5 and
Nur77 responds rapidly to ISO stimulation in the PC12 adrenal chromaffin cell line (see Supplementary material online, Figure S1B and C). This prompted us to investigate the relation between Nur77 and NPY in the sympathoadrenal axis.
Nur77 represses NPY expression in the sympathoadrenal-cardiac axis
To examine whether Nur77 controls NPY expression, we performed gain-and loss-of-function experiments in PC12 cells. Overexpression of Nur77 (see Supplementary material online, Figure S2A ) resulted in down-regulation of NPY expression and concomitant lower NPY secretion into the culture medium ( Figure 2A) . Conversely, siRNA-mediated Nur77 knockdown (see Supplementary material online, Figure S2B ) resulted in higher NPY expression and higher NPY secretion into the culture medium ( Figure 2B ). These data demonstrate that Nur77 represses NPY expression and release from chromaffin cells in vitro. In line with these findings, analysis of the sympathoadrenal-cardiac axis in Nur77-KO mice revealed higher NPY mRNA and protein expression in adrenal glands ( Figure 2C ), increased NPY plasma levels ( Figure 2D ), and enhanced cardiac NPY protein levels ( Figure 2E ) compared to WT mice. Cardiac NPY mRNA was undetectable (see Supplementary material online, Figure S3 ), suggesting that the higher cardiac NPY levels in Nur77-KO mice arise from higher NPY influx into the heart. Importantly, when studying NPY mRNA expression in other tissues, including the brain where NPY plays a prominent role, no significant differences between WT and Nur77-KO were found, except in bone marrow-derived macrophages (see Supplementary material online, Figure S3 ), as previously reported. Transcripts assessed by qPCR, secreted NPY was measured by ELISA in conditioned medium; n = 5-6 independent experiments. (C) In Nur77-deficient (Nur77-KO) mice, NPY mRNA and protein are significantly higher in adrenal glands, plasma (D), and heart (E) as measured by western blot and ELISA, n = 7-8 mice per group. Data are presented as mean ± SEM (Student's t-test) or median ± IQR (C left panel; Mann-Whitney U test); *P < 0.05, **P < 0.01, ***P < 0.001. Figure 3 Paracrine control of cardiomyocyte hypertrophy by Nur77 via NPY-NPY1R signalling. Hypertrophy was assessed in neonatal rat cardiomyocytes (NRCM) by surface area measurement of a-actinin-positive cells. Per group, >500 NRCMs were assessed in four to five independent experiments. Scale bar represents 50 mm. (A) NPY-induced NRCM hypertrophy is inhibited by pre-incubation of NPY receptor type 1-specific antagonist BIBO3304 (1 lM). (B) siNur77-PC12 cell conditioned medium induces significantly more NRCM hypertrophy than siCon-PC12 conditioned medium, which is inhibited by BIBO3304. Conditioned medium was pooled from five independent PC12 knockdown experiments. (C) Nur77-KO mouse serum induces significantly more hypertrophy in NRCMs than WT mouse serum, which is inhibited by BIBO3304. Serum was pooled from 4 to 6 mice per group. (D) Isoproterenol (ISO, 25 lM) synergistically causes NRCM hypertrophy with Nur77-KO serum, which is significantly inhibited only upon combined treatment with b-blocker metoprolol (METO, 10 lM) and NPY1R antagonist BIBO3304; n = 4-6 independent experiments. Data are presented as mean ± SEM; ANOVA with Bonferroni post-correction; *P < 0.05, **P < 0.01, ***P < 0.001.
Nur77 limits sympathoadrenal-cardiac NPY
Nur77 controls cardiomyocyte hypertrophy in a paracrine manner via NPY-NPY1R signalling NPY is known to induce cardiomyocyte hypertrophy. Accordingly, in neonatal rat cardiomyocytes (NRCMs), we observed a dose-dependent increase in cell surface area in response to NPY ( Figure 3A) . Since NPY is known to elevate cardiomyocyte [Ca 2þ ] i via the NPY type 1 receptor (NPY1R) 9 and altered Ca 2þ homeostasis plays a critical role in cardiomyocyte hypertrophy, 4 we assessed the involvement of NPY1R in NPYinduced NRCM hypertrophy. Indeed, the NRCM cell surface area increase was largely inhibited by pre-incubation with the NPY1R-selective antagonist BIBO3304, 26 showing larger inhibitory effects at higher NPY concentrations ( Figure 3A) . To assess whether Nur77 regulates cardiomyocyte hypertrophy in a paracrine manner via NPY, NRCMs were cultured with conditioned medium from PC12 cells differentially expressing Nur77. In agreement with the effect of Nur77 on NPY secretion into culture medium, conditioned media from Nur77-silenced PC12 cells induced more hypertrophy compared to control-conditioned medium. The NPY1R antagonist BIBO3304 inhibited hypertrophy only in NRCMs stimulated with conditioned medium from Nur77-silenced cells, which has a higher concentration of NPY than control medium ( Figure 3B ). To extend these results, NRCMs were treated with serum from WT or Nur77-KO mice in the absence or presence of BIBO3304. NRCMs stimulated with Nur77-KO serum were significantly larger compared to WT serum-stimulated cells. Again, this effect was mediated by NPY since NPY1R antagonism only had a significant inhibitory effect on hypertrophy of Nur77-KO serumstimulated NRCMs ( Figure 3C ).
Since Nur77-KO mice show enhanced cardiac hypertrophy upon chronic b-adrenergic stimulation, 22 we next assessed the paracrine modulation of NRCM hypertrophy by Nur77 via NPY in the context of a cardiac insult. To do so, NRCMs were co-stimulated with b-adrenergic agonist ISO to induce hypertrophy. As expected, ISO enhanced hypertrophy in both WT-and Nur77-KO serum-treated NRCMs ( Figure 3D ). The b-adrenergic receptor antagonist metoprolol (METO) was sufficient to inhibit ISO-induced hypertrophy in WT serum-treated NRCMs. However, a combination of both METO and BIBO3304 was necessary to significantly inhibit ISO-induced hypertrophy in NRCMs treated with serum from Nur77-KO mice. Cell size was now back to WT serumstimulated levels. These results suggest that elevated circulating NPY levels in Nur77-KO mice exert a significant hypertrophic effect on cultured NRCMs, even upon b-adrenergic insult and in the presence of b-blockade. The NPY type 5 receptor has also been reported to mediate NPYinduced cardiomyocyte hypertrophy. 27 However, NPY5R antagonism using specific antagonist A972 did not inhibit Nur77-KO serum-induced NRCM hypertrophy, while antagonism of NPY1R does (see Supplementary material online, Figure S4 ). Nur77 regulates cardiomyocyte NPY1R signalling in a cell-specific manner
Our results suggest that Nur77 influences NPY-mediated signalling at the level of production and secretion in the adrenal gland, and at the cardiomyocyte level. Therefore, to delineate to what extent full-body Nur77 deficiency or cardiomyocyte-specific Nur77 deficiency affects the NPY-NPY1R-induced cardiomyocyte [Ca 2þ ] i response, we generated cardiomyocyte-specific Nur77-KO mice (CM-KO). Transgenic expression of Cre under control of the a-MHC promoter led to a 75% reduction of Nur77 expression in total heart tissue compared to littermate controls (CM-WT), whereas expression was unaltered in skeletal muscle (see Supplementary material online, Figure S5A ). As expected, cardiomyocyte-specific deficiency of Nur77 resulted in normal NPY levels in the adrenal gland, plasma, and in the heart ( Figure 5A-C) . In line with these data, serum from CM-KO mice induced NRCM hypertrophy to the same extent as CM-WT serum. Additionally, NPY1R antagonism had no effect on NRCM hypertrophy (see Supplementary material online, Figure S5B ), indicating that there is no paracrine NPY effect on cardiac function in CM-KO mice.
Having established the peripheral NPY levels are unchanged in CM-KO mice, we assessed whether cardiomyocyte [Ca 2þ ] i was altered in these mice. Interestingly, similar to full-body Nur77-KO mice, cardiomyocyte-specific Nur77 deficiency is sufficient to increase baseline and NPY-induced diastolic, systolic, and peak amplitude [Ca 2þ ] i in isolated CM-KO cardiomyocytes ( Figure 5E ). NPY1R antagonism significantly decreased NPY-induced [Ca 2þ ] i elevations in CM-KO cardiomyocytes, but not in CM-WT, indicating a cardiomyocyte-intrinsic role for Nur77 in NPY1R signalling. We considered the possibility that, acting as a transcription factor, Nur77 regulates expression of NPY1R in cardiomyocytes. However, this was not the case as expression of NPY1R mRNA was comparable in Nur77-KO and CM-KO cardiomyocytes compared to their controls (see Supplementary material online, Figure S6 ).
ISO-induced cardiac remodelling in Nur77-KO mice is attenuated by NPY1R antagonism
So far, our results demonstrate that elevated circulating NPY levels in Nur77-KO mice induce NRCM hypertrophy in a synergistic manner with ISO in vitro and that elevated [Ca 2þ ] i in Nur77-deficient cardiomyocytes can be reduced by NPY1R antagonism ex vivo. Therefore, we next investigated the role of NPY-NPY1R signalling in Nur77-deficient mice on cardiac remodelling in vivo.
To induce adverse cardiac remodelling, mice were chronically stimulated with ISO in the absence or presence of BIBO3304, using osmotic minipumps. After 1 week of chronic infusion, ISO caused significant cardiac fibrosis ( Figure 6A ) and cardiomyocyte hypertrophy ( Figure 6B ) in all experimental groups, showing efficacy of the model. Interestingly, both Nur77-KO and CM-KO mice displayed enhanced cardiac fibrosis ( Figure  6A ) and cardiomyocyte hypertrophy ( Figure 6B effect on fibrosis and hypertrophy in Nur77-KO mice, whereas it did not in CM-KO or WT mice.
The observed cardiac pathology was reflected in plasma NPY levels ( Figure 6C ). ISO infusion significantly elevated plasma NPY in WT, CM-WT, and CM-KO mice compared to control-treatment. Since Nur77-KO mice already had significantly higher plasma NPY levels under control conditions, ISO did not further elevate these. Interestingly, a trend (P = 0.09) towards decreased plasma NPY was observed upon NPY1R antagonism in ISO-treated Nur77-KO mice. These data demonstrate the importance of the elevated baseline NPY levels in Nur77-KO mice.
We next assessed if the observed hypertrophy and the antihypertrophic effect of BIBO3304 in Nur77-KO mice may be mediated by calcineurin. Calcineurin is known to be activated by sustained [Ca 2þ ] i elevation, 28 and its expression is increased by NPY infusion, 12 both of which are present in Nur77-KO mice. Indeed, chronic infusion of NPY1R antagonist BIBO3304 significantly reduced the elevated cardiac calcineurin activity in Nur77-KO mice, while having no effect in WT or CM-KO mice ( Figure 6D ), illustrating the significance of enhanced NPY-mediated signalling to cardiac hypertrophy in full-body Nur77-KO mice. Together, these data suggest that cardiomyocyte-specific Nur77 deficiency is sufficient to cause excessive cardiac remodelling upon chronic ISO stimulation. However, in the CM-KO mice, remodelling is not inhibited by BIBO3304, suggesting that NPY1R-mediated signalling is not the key mechanism causing damage upon ISO infusion. In full-body Nur77-KO mice, NPY1R antagonism significantly inhibits cardiac fibrosis and hypertrophy, thereby demonstrating the additive effect of elevated starting levels of circulating NPY together with altered NPY1R signalling to ISOinduced cardiac remodelling.
NPY is a potent vasoconstrictive co-transmitter and NPY1R antagonism is known to inhibit this action. 29 Therefore, we next assessed whether an NPY/NPY1R-related vascular phenotype in Nur77-KO mice may underlie their cardiac remodelling outcome. Using myography, we measured NPY-induced vasoconstriction in WT and Nur77-KO mesenteric arteries pre-constricted with norepinephrine. However, no significant differences in concentration-response curves between WT and Nur77-KO arteries were observed. This is in line with previous reports that the Nur77-KO mice do not have enhanced blood pressure at baseline or upon angiotensin II infusion. 30 ,31 Furthermore, we show that BIBO3304 completely inhibited NPY-induced vasoconstriction in both (1 lM) in CM-KO cardiomyocytes, but not in CM-WT. Per group n = 3 mice, n = 9-11 cardiomyocytes; data presented as mean ± SEM; area under the curve (AUC) tested by ANOVA with Bonferroni post-correction; *P < 0.05, **P < 0.01, ***P < 0.001. In A, data are presented as median ± IQR (Mann-Whitney U test), in B-C as mean þ SEM (Student's t-test). WT and Nur77-KO mice (see Supplementary material online, Figure  S7A ). Additionally, ISO infusion in the mice enhanced cardiac perivascular fibrosis, while BIBO3304 treatment had no inhibitory effect on perivascular fibrosis in either experimental group (see Supplementary material online, Figure S7B ). Taken together, these results suggest that an NPY/NPY1R-related vascular pathology does not likely contribute to the enhanced cardiac remodelling in Nur77-KO mice.
In conclusion, our data show that Nur77 acts as a repressor of adrenal NPY expression and thereby circulating NPY. Additionally, cardiomyocyte NPY1R-mediated signalling is modulated by Nur77 in a cell-specific manner. Together, Nur77 protects against adverse cardiac remodelling by affecting the NPY-NPY1R signalling pathway on multiple levels of the sympathoadrenal-cardiac axis ( Figure 7 ).
Discussion
Cardiac function is modulated by the sympathetic nervous system, and aberrant compensatory sympathetic activation is a prominent characteristic of heart failure. 1 Next to catecholamines, co-transmitters including NPY are also released. After a week of chronic ISO infusion, plasma norepinephrine in mice was significantly decreased, while plasma NPY was significantly elevated. It is believed that norepinephrine is released upon lower intensity and frequency sympathetic activation, while NPY is released upon intense and prolonged high-frequency sympathetic activation. 32 Differences in NPY and norepinephrine release kinetics, but also expression of npy and tyrosine hydroxylase genes, upon various degrees of stress have been reported before. 21, 33 Nuclear receptor Nur77 responds to sympathetic stimulation in various organs, including the heart and adrenal glands, 22, 34 and could thus be an interesting novel target in adverse cardiac remodelling and heart failure. To the best of our knowledge, this is the first report linking Nur77 to NPY in the context of cardiac function. We show that Nur77 represses NPY expression and release from adrenal chromaffin cells. In Nur77-KO mice, this leads to elevated NPY levels in the sympathoadrenal-cardiac axis. The main sources of peripheral NPY are adrenal chromaffin cells, sympathetic nerves and platelets. 32 Since both NPY mRNA and protein are elevated in Nur77-KO adrenal glands, we propose that increased plasma levels of NPY in Nur77-KO mice originate from the adrenal glands. Whether the elevated cardiac NPY in Nur77-KO mice is taken up from the circulation, originates from intracardiac sympathetic neurons, or both, is at present unknown. As mentioned before, Nur77-deficient macrophages express markedly higher NPY. 16 It is known that enhanced infiltration of pro-inflammatory monocytes into the myocardium and their differentiation to inflammatory macrophages after myocardial infarction (MI) causes worsened post-MI outcome in Nur77-KO mice. 35 However, whether NPY plays a role in this context is at present unknown and deserves further elucidation. In our experiments, monocyte infiltration is hardly present in the 1-week model of ISO-induced cardiac hypertrophy and fibrosis (data not shown). Therefore, we consider the contribution of macrophagederived NPY unlikely. We show that conditioned medium from Nur77-silenced chromaffin cells and serum from Nur77-KO mice induce NRCM hypertrophy via NPY. However, we and others have also reported that siRNA-mediated Nur77 silencing in NRCMs themselves induces hypertrophy. 22, 36 Figure 7 ] i in Nur77-KO mice. 22 Thus, further transcriptome analyses need to be performed in CM-KO mice to identify Nur77 target genes in cardiomyocytes, which underlie this NPY/NPY1R-independent elevated Ca 2þ phenotype.
Interestingly, it has recently been reported that Nur77 blunts storeoperated Ca 2þ entry (SOCE) in NRCMs in a non-genomic fashion by enhancing O-GlcNAcylation of the SOCE regulator Stim1, impairing its function. 38 Elevated plasma NPY independently correlates to disease severity in congestive heart failure patients 14, 39 and is an independent prognostic marker for 1-year mortality risk. 15 Furthermore, significantly higher plasma NPY levels were observed at hospital admission in MI patients with worsened reperfusion indices after coronary intervention. 40 Since sympathetic activity is increased in heart failure, and NPY is released upon prolonged higher-intensity sympathetic activity, 32 elevated plasma NPY in heart failure patients indeed may reflect a more severe disease state. Together with the emerging knowledge on pathophysiological actions of NPY, these reports plead for further validation of NPY as a biomarker and therapeutic target in heart failure. Whether Nur77 has a role in regulating NPY in human cardiac disease has yet to be assessed. However, interestingly, a shared phenotype between Nur77 and NPY seems to be present in asthma patients. Three Nur77 single nucleotide polymorphisms have been identified to associate with bronchial hyperresponsiveness in asthma patients. 41 Accordingly, NPY causes hyperresponsiveness in human airway explants 42 and significantly elevated NPY plasma levels are found in asthma patients. 43 Further studies are required to determine whether Nur77 is indeed a direct transcriptional inhibitor of NPY in human disease. Interestingly, recently, a potential Nur77 regulatory element in the human NPY gene has been identified in a myeloblast cell line. 44 Our data and these reports together prompt a study of these Nur77 single nucleotide polymorphisms in relation to plasma NPY levels and heart failure to identify Nur77 as a novel modifier in cardiac remodelling and thereby a promising therapeutic target.
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